Biotech, Biopharma Stocks to Watch: (BLGX), (OTC: IGXT; TSX: IGX.V) (SNTS)




Point Roberts WA – April 30, 2013 – (www.investorideas.com newswire) , Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks announces recent biotech and biopharma stocks (OTC:BLGX), (OTC: IGXT; TSX: IGX.V) and (SNTS) added to the biotech stock directory at Investorideas.com.



The stock directories include stocks on the TSX, OTC, NASDAQ, NYSE, ASX and other leading exchanges.



Biologix Hair, Inc. (OTC:BLGX) together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide. BHS is currently focused on obtaining FDA approval for its breakthrough hair-loss prevention and regeneration drug formulation, while simultaneously developing a global distribution network of licensed clinicians and medical practitioners seeking to obtain exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™. Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies owned and operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to obtain the certified Biologix Hair Therapy Center™ designation and with it exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™. Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted, which may or may not be forthcoming. Therefore, the Biologix Hair Therapy System™ is not yet available; other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.



IntelGenx (OTC: IGXT; TSX: IGX.V) is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management.



Santarus, Inc. (NasdaqGS: SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on

FENOGLIDE® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol. In March 2013, the company plans to begin promoting UCERIS™ (budesonide) extended release tablets for the induction of remission of active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders. Santarus’ product development pipeline includes the investigational drug RUCONEST® (recombinant human C1 esterase inhibitor) for treatment of acute attacks of hereditary angioedema. The company expects to submit a biologics license application (BLA) to the U.S. Food and Drug Administration for RUCONEST in the first half of 2013. Santarus is also developing rifamycin SV MMX®, which is in Phase III clinical testing for treatment of travelers’ diarrhea. In addition, SAN-300, the company’s investigational monoclonal antibody, is in Phase I clinical testing.





Visit Investorideas.com each day for new investing ideas and more about how the stock market works

Investors can research more biotech stocks with Investorideas.com stock directories





About InvestorIdeas.com: Investor Ideas for global investors

www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.



The Investor Ideas newswire is a news source on Google news, Google Currents and Linkedin.com/Today news. Investorideas.com newswire is now available as a free mobile app for iPhone orAndroid. Go here or here for link



Follow Investorideas.com on Twitter

Follow Investorideas.com on Facebook

Follow Investorideas.com News on Linkedin.com/today



Sign up for free stock alerts at Investorideas.com



Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in over 14 leading sectors





Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products

or securities. http://www.investorideas.com/About/Disclaimer.asp

This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com